Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma

2016-11-30 15:45:10 | BioPortfolio


Paclitaxel In combination with DDP and 5-FU(TPF) as neoadjuvant chemotherapy in treating boundary resectable locally advanced esophageal squamous cell carcinoma: A phase II clinical trial.


Esophageal cancer is one of the most common malignant tumor in China. In Asian countries, esophageal squamous carcinoma is the main pathological type of esophageal carcinoma. Prognosis of esophageal squamous carcinoma is usually poor and surgery is the only radical treatment. However, the optimal therapy pattern for local advanced esophageal carcinoma is still unclear. Part of the patients that clinical staging as T4 and presents multiple lymph node metastasis and esophageal carcinoma with large diameters are initially diagnosed as boundary resectable, which means patients may be able to undergo R0 resection. However, for patients who are diagnosed as boundary resectable esophageal carcinoma, there are still no sufficient studies implicate that how to improve R0 resection rate by neoadjuvant chemotherapy. DDP in combination with 5-FU and docetaxel regimen(DCF) was reported as effective neoadjuvant chemotherapy in treating esophageal squamous carcinoma. However, studies also showed that the DCF regimen caused severe adverse reaction. The mechanism of paclitaxel is similar to docetaxel while with less adverse events than docetaxel. Based on the research situation mentioned above, the investigators decided to conduct a phase II clinical trial to further explore the efficacy and safety of paclitaxel in combination with DDP and 5-FU (TPF) regimen in treating locally advanced esophageal squamous cell carcinoma.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Esophageal Squamous Cell Carcinoma




Sun Yat-sen University Cancer Center




Sun Yat-sen University

Results (where available)

View Results


Published on BioPortfolio: 2016-11-30T15:45:10-0500

Clinical Trials [4136 Associated Clinical Trials listed on BioPortfolio]

Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus

The purpose of this study is to determine which regimen is better for esophageal squamous carcinoma in concurrent chemoradiation(CCRT),paclitaxel or S1 plus cisplatin.

Nimotuzumab Combined Paclitaxel and Cisplatin Treatment of Metastatic Esophageal Squamous Cell Carcinomas Clinical Study

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin...

Erbitux Combined With Chemo-Radiotherapy in Esophageal Squamous Cell Carcinoma

The purpose of this study is to determine whether the treatment of loco-regional esophageal squamous cell carcinoma with cetuximab in combination with paclitaxel, cisplatin and radiation ...

Compare Paclitaxel and Cisplatin,Paclitaxel and Fluorouracil, Paclitaxel and Carboplatin Concurrent With Radiotherapy in Local Advanced ESCC

The purpose of this study is to determined the best scheme in paclitaxel and cisplatin,paclitaxel and fluorouracil,paclitaxel and carboplatin in the treatment concurrent with radiother...

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main path...

PubMed Articles [18358 Associated PubMed Articles listed on BioPortfolio]

A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.

This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been p...

Nestin expression involves invasiveness of esophageal carcinoma and its downregulation enhances paclitaxel sensitivity to esophageal carcinoma cell apoptosis.

Paclitaxel has been generally used to treat primary and metastatic esophageal carcinoma. It has been shown that nestin is highly expressed in esophageal carcinoma and that there is a strong associatio...

Helicobacter Pylory infection in patients with esophageal squamous cell carcinoma.

Esophageal squamous cell carcinoma is one of the most common esophageal diseases in the developing world, but the relationship between esophageal squamous cell carcinoma and Helicobacter pylori infect...

DEC2 expression antagonizes cisplatin‑induced apoptosis in human esophageal squamous cell carcinoma.

Differentiated embryonic chondrocyte expressed gene 1 (DEC1) and differentiated embryonic chondrocyte expressed gene 2 (DEC2) belong to the Hairy/Enhancer of Split subfamily of basic helix‑loop‑he...

Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.

This study was conducted to investigate the efficacy and toxicity of combination treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy with paclitaxel plus different plati...

Medical and Biotech [MESH] Definitions

A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.

Unusual tumor affecting any site of the body, but most often encountered in the head and neck. Considerable debate has surrounded the histogenesis of this neoplasm; however, it is considered to be a myoblastoma of, usually, a benign nature. It affects women more often than men. When it develops beneath the epidermis or mucous membrane, it can lead to proliferation of the squamous cells and mimic squamous cell carcinoma.

An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

More From BioPortfolio on "Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma"

Quick Search

Searches Linking to this Trial